Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes

Part of paid clinical trials in Dallas, Texas.

Sponsor
University of Texas Southwestern Medical Center
Study ID
NCT06593314
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Message with EchoGo — BEHAVIORAL
    This alert will inform the provider that the patient has subclinical HFpEF
  • Standard Message — BEHAVIORAL
    This alert will inform the provider of guideline directed treatment options for patients with diabetes to prevent heart failure.

Study Details

A pragmatic electronic health record (EHR) based randomized controlled trial to evaluate the utility of providing Ultromics EchoGo analysis results and recommendations for HF risk prevention therapies using an EHR embedded clinical decision support tool.

Key Dates

Start date
Aug 6, 2025
Status verified
May 2026
Primary completion
Sep 15, 2026
Completion
Oct 15, 2026

Study Design

Enrollment
800 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: EHR Alert Group
    Provider will receive a computer-based alert notifying them that the patient has subclinical HFpEF as determined by the Ultromics EchoGo algorithm and associated guideline recommendations for the management of these patients. The alert will include guideline-based and standard-of-care recommendations for the use of SGLT-2 inhibitors and/or GLP-1 RA (if obesity is present). The purpose of the alert is to inform the providers about the risk of heart failure and provide them guidance regarding the guideline-recommended standard of care. The providers can choose to provide care as deemed fit based on the information provided
  • Active Comparator: Standard Message Group
    We will provide a standard message to the provider detailing guideline-recommended medications for type 2 diabetes. This will not contain information about the Ultromics EchoGo algorithm. The providers can choose to provide care as deemed fit based on the information provided

Primary Outcome Measure

Frequency of prescription of SGLT-2i medication at outpatient clinic visits over 3 months follow-up [ Time Frame: 3-month follow-up ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UT Southwestern Medical CenterDallasTexas75235
Ambarish Pandey, MD,MSCS
214-645-9762

Find similar trials in Dallas, TX

By condition
Heart failure
By specialty
CardiologyHeart disease
By research site
UT Southwestern Medical Center· Dallas, TX

Related Studies